ACD - a Bio-Techne brand, is a pioneer and leader in the advancement of spatial genomics and clinical applications by unlocking the power of RNA and developing cell- and tissue-based research and diagnostic tests for personalized medicine.
Based in Silicon Valley, ACD’s proprietary RNAscope™ technology, the first multiplex fluorescent and chromogenic in situ hybridization platform, enables detection and quantification of single RNA molecules in situ. Our portfolio includes, RNAscope, BaseScope™, miRNAscope™ and HiPlex™ v2. With over 44,000 probes and our Professional Assay Services, we enable rapid assessment of unique targets. Since launch in 2011, the technology boasts 5,225+ citations, with new peer reviewed publications daily.
Based on proprietary technology, ACD’s RNAscope Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform enables detection and quantification of RNA in situ at single molecule sensitivity.